Navigation Links
Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
Date:11/7/2011

6,436,708Deferred revenue, net of current portion

81,853

72,780Deferred revenue from affiliated entity, net of current portion

2,055,444

2,336,694Deferred rent

68,280

67,112Deferred tax liabilities

53,186

53,186Total liabilities11,962,364

8,966,480Stockholders' equity:Inovio Pharmaceuticals, Inc. stockholders' equity:Common stock

127,257

105,038Additional paid-in capital

255,238,121

241,233,334Accumulated deficit

(204,614,933)

(194,838,229)Accumulated other comprehensive income

(5,206)

2,850Total Inovio Pharmaceuticals, Inc. stockholders' equity50,745,239

46,502,993Non-controlling interest

558,716

597,918Total stockholders' equity

51,303,955

47,100,911Total liabilities and stockholders' equity$  63,266,319

$  56,067,391INOVIO PHARMACEUTICALS, INCCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)Three Months Ended
September 30,Nine Months Ended
September 30,2011201020112010Revenue:License fee and milestone revenue

$  76,888

$  39,330

$  129,712

$  161,825License fee and milestone revenue from affiliated
  entity

106,250

93,750

305,208

219,556Grant and miscellaneous revenue

2,454,423

1,075,563

7,727,669

3,335,510Miscellaneous revenue from affiliated entity

67,900

67,900Total revenue2,637,561

1,276,543

8,162,589

3,784,791Operating expenses:Research and development

6,987,824

2,951,067

15,873,601

8,764,891General and administrative

2,323,188

2,881,994

8,734,806

8,959,745Gain on sale of assets

(337,000  )

(587,000  )

—Total operating expenses8,974,012

5,833,061


'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... 2014 Intarcia Therapeutics, Inc. today ... its lead candidate ITCA 650 (continuous subcutaneous delivery of ... HbA1c levels at the 50 th Annual Meeting ... (EASD). Data from the open-label, phase 3 FREEDOM-HBL (high ... in patients with poorly controlled type 2 diabetes. The ...
(Date:9/19/2014)... 2014 Reductions in kidney failure ... in people with diabetes type 2 "Intensive ... for the kidneys." Australian researchers have discovered ... diabetes leads to persistent reductions in kidney failure many ... global study has found that, five and a half ...
Breaking Medicine Technology:New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... SAN DIEGO, Jan. 7 Trius Therapeutics, Inc. ... clinical trial of TR-701, an,antibacterial drug candidate intended ... including those caused by MRSA,and other drug-resistant strains. ... will test tolerability, safety and,pharmacokinetics of the oral ...
... Ill., Jan. 7 Baxter International,Inc. (NYSE: ... pre-clinical,programs to develop recombinant Factor IX proteins to ... recombinant Factor IX therapy for,treatment of acute bleeding ... Factor IX therapy for prophylaxis of bleeding in,hemophilia ...
Cached Medicine Technology:Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 3
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... over the five years to 2014. Industry operators were ... time during the period, as well as establish distribution ... is due in large part to its novelty; energy ... Nevertheless, in that time, industry operators have been able ...
(Date:9/19/2014)... MD & Salt Lake City, UT (PRWEB) September 19, ... to launch the new Activz Greens Smoothie ... Products Expo East, September 18th-20th in Baltimore, MD. ... with 8 organic super foods combined in one convenient ... Natural Products Expo East, September 18th-20th in Baltimore, MD. ...
(Date:9/19/2014)... (SALT LAKE CITY)A new study by researchers at the ... a longstanding question about the role of mitochondria in ... a new mouse model to study such illnesses. ... Ph.D., professor of biochemistry, found that when healthy, functioning ... fibers that conduct electricity away from neurons mice ...
(Date:9/19/2014)... as Johne,s disease, is caused by the bacterium ... Austria, there is a legal obligation to report ... treatment-resistant diarrhoea and wasting among affected animals. The ... farms. The animals produce less milk, exhibit fertility ... such as udder inflammation. , To date ...
(Date:9/19/2014)... 19, 2014 Lifeinsure.biz has released ... riders that can be purchased without medical examinations. ... and make a life insurance policy more advantageous. Clients ... more about extra options available for a no medical ... medical examinations required is simple to purchase, however it ...
Breaking Medicine News(10 mins):Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 2Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 3Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 2Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 3Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:No Medical Exam Life Insurance - Lifeinsure.biz Presents 5 Important Riders! 2
... found to be the combination of dry eyes and mouth//, ... symptoms include dry, gritty or burning eyes, intermittent blurry vision, ... enlarged parotid glands. The parotids are a pair of salivary ... Other signs and symptoms may include dry skin or vaginal ...
... treatments has been accused of placing money before patients//, ... drug. <BR.,Patients suffering from cancer linked to asbestos will ... is pemetrexed disodium, after a study conducted ... ,The group analyzed the cost effectiveness of the ...
... new fat-busting laser treatment called SmartLipo. It is to be ... less invasive form of liposuction//. It removes unsightly lumps of fat ... About six cosmetic surgery clinics in London, the Midlands and the ... Food and Drug Administration (FDA) has not approved to the procedure ...
... investigators at John Hopkins Children’s Center//, patient’s safety system can ... errors into a computer database. ,Hopkins researchers ... reporting on the errors voluntarily plus steps taken to overcome ... not new, but few studies have looked at the accuracy ...
... commercial production at its Dehradun unit. // ,The ... pharmacuetical formulations unit would achieve a capacity level of 300 ... in stages., ,Plans of establishing a parenterals division at ... the company was trading at Rs 102.35, down 4.48 per ...
... have died after catching bird flu from wild swans//. ... said that they had occurred earlier this year. They also went ... avian flu that were being passed on from the wild birds. ... a village in Azerbaijan, and are believed to have caught the ...
Cached Medicine News:Health News:Voluntary Error-Reporting System Ensures Patient Safety 2Health News:Voluntary Error-Reporting System Ensures Patient Safety 3Health News:Voluntary Error-Reporting System Ensures Patient Safety 4Health News:Four Deaths Due To Bird Flu Caught From Wild Birds 2
For the quantitative in vitro determination of Apolipoprotein A-1 in human serum....
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
The BUN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of urea nitrogen in serum, plasma and urine....
The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
Medicine Products: